Administration of pneumoperitoneum and botulinum toxin in abdominal wall reconstruction

Safety and effectiveness of preoperative progressive pneumoperitoneum and botulinum toxin administration before abdominal wall reconstruction in patients with complex ventral hernia with loss of domain.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230408057846N1

Enrollment

Registered

2023-06-18

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large abdominal wall hernia with loss of domain. Unspecified abdominal hernia without obstruction or gangrene

Interventions

Intervention group: 500 units of botulinum A (Masport, MasoonDarou Pharmaceutical Company, Iran) are mixed in 50 ml of normal saline. Under ultrasound guidance, it is injected in three layers of inter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Abdominal incisional hernia with loss of domain Referring for abdominal wall reconstructive surgery

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study. A history of allergy to Botox.

Design outcomes

Primary

Measure	Time frame
The volume of the abdominal cavity. Timepoint: Before and one month after botulinum and pneumoperitoneum injection. Method of measurement: Measurement of the the abdominal cavity volume by CT scan.;Hernia volume. Timepoint: Before and one month after botulinum and pneumoperitoneum injection. Method of measurement: Measurement of the the hernia volume by CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Yousefi Rudsari

Mashhad University of Medical Sciences

yousefirmr981@mums.ac.ir+98 51 3833 2043

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026